Hints and tips:
Related Special Reports
...Prime Minister Boris Johnson visited it in September last year....
...Vaccine makers including GSK, Pfizer, Moderna and Johnson & Johnson, are racing to find a jab for RSV....
...“Multiple positive developments alongside a clear path set towards reopening warrant an upgrade,” they wrote in a research report....
...Extracts from his discussion with Alix Steel and Guy Johnson: AS: Were you aware of this risk when using the platform?...
...Both Johnson & Johnson and Novavax have said their vaccines were less effective against the strain in clinical trials conducted in South Africa....
...But while these developments will have been disappointing to Wood’s legions of fans, the sell-off will have come as no surprise to a team of investment academics: their latest research suggests that investors...
...These companies spent $47bn on research and development over the 30 months, as well as issuing $14bn in new stock....
...The pandemic has compressed into months vaccine research and development that can take years....
...Mathai Mammen, global head of Janssen Research & Development at Johnson & Johnson, said: “We look forward to discussing with public health officials a potential strategy for our Johnson & Johnson Covid-19...
...Mathai Mammen, global head of Janssen Research & Development at Johnson & Johnson, said the company looked forward to “discussing with public health officials a potential strategy for our Johnson & Johnson...
...Mathai Mammen, global head of Janssen Research & Development at J&J said the data showed that the vaccine offers “potentially a dual mechanism of protection against Covid-19 disease, including against the...
...There are also questions about the role played by a company that acted as intermediary and why the contract was signed ahead of deals with Pfizer and Johnson & Johnson’s pharma division Janssen, even though...
...J&J is preparing to test a new formulation that could be targeted at the 501.v2 variant, but Mathai Mammen, global head of research and development for Janssen, J&J’s pharmaceuticals division, said he was...
...Johnson & Johnson Us The drugmaker’s phase 3 trial is ongoing in the US, with interim data expected in January....
...It is now time to do the same for tech development: a proposal I call the “Technology 10”....
...Last December JNJ-4528, a Johnson & Johnson (J&J) cell therapy, was deemed by the FDA to be a “breakthrough” treatment, a designation granted to therapies that show promise in treating serious or life-threatening...
...Mathai Mammen, global head of Janssen Research and Development, a subsidiary of Johnson & Johnson, said Spravato was a “unique and innovative medicine” that had the potential to offer “new hope” to the third...
...But a more precise understanding of biology has led pharmaceutical companies to focus research and development efforts on treatments for rarer diseases, often aimed at small sub groups with a particular...
...Since then other partnerships have been announced, including agreements with Janssen, a pharmaceutical arm of Johnson & Johnson, and AstraZeneca....
...“The Car-T technology is moving very quickly,” says Peter Lebowitz, global head of oncology at Janssen, the drugmaking unit of Johnson & Johnson....
...The 49-year-old is now commercial lead for haematology at Janssen, Johnson & Johnson’s pharmaceutical arm....
...Legend also piqued the interest of executives at Johnson & Johnson, the world’s largest healthcare company....
...Ben Johnson, director of passive funds research at Morningstar, the data provider says: “State Street historically suffered from a lack of focus on the ETFs that make the core building blocks of investors...
...Ben Johnson, director of global ETF research at Morningstar, thinks BlackRock and Vanguard will continue to dominate the leader board....
International Edition